XMHQ Invesco S&P MidCap Quality ETF

Expense Ratio
0.25%
Dividend
0.58%
Previous close
$112.65
Est. 12 months change
+22.17%
Projected Price
$137.62

Profitability Metrics

Return on Equity (ROE)
34.88%
Return on Assets (ROA)
11.15%
Return on Invested Capital (ROIC)
68.19%
Weighted Average Cost of Capital (WACC)
8.95%
ROIC - WACC
59.24%
Updated : 2026-10-07 23:28 ET

Valuation Metrics

P/E Ratio
18.10
Forward P/E
16.55
PEG Ratio
1.87
Debt Current Ratio
2.27

Growth & Cash Flow

Gross Margin
50.08%
Operating Margin
22.30%
FCF Margin
22.08%
TTM Revenue Growth
13.69%
Projected 12M EPS Growth
9.34%
The above metrics represent weighted averages, calculated using each stock's individual value weighted by its proportion of ETF holdings.

Top 10 Holdings

Stock TickerWeight
FTI4.44%
MEDP3.64%
NVT3.61%
MANH3.33%
EXEL3.32%
UTHR2.96%
CW2.71%
CRS2.25%
CSL2.24%
LECO2.15%

ETF Analysis

Fund Overview

Invesco S&P MidCap Quality ETF (XMHQ) currently reports 79 stock positions (subject to change), placing it in the moderately spread range by holdings breadth. The top line-up is FTI (4.44%), MEDP (3.64%), NVT (3.61%), with FTI as the largest single weight at 4.44%. Together, the top three holdings account for 11.69%, which does not represent a dominant share, indicating less concentration in the very top of the book. The overall construction balances concentrated exposure at the top with broader diversification through the rest of the book.

Profitability & Capital Efficiency

Through the lens of capital efficiency, ROIC is 68.19%, WACC is 8.95%, and the economic spread is 59.24%. On balance, reinvested capital is working exceptionally hard, with operating returns clearing the funding cost hurdle by a wide margin. Supporting metrics show ROE at 34.88% and ROA at 11.15%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.

Valuation

Assessed on a multiple basis, trailing P/E of 18.10, forward P/E of 16.55, PEG of 1.87. Forward P/E tracks closely with trailing P/E — a sign that the market sees the current earnings run rate as a reasonable baseline going forward. Growth-adjusted, the multiple is in an acceptable range — the portfolio is neither pricing in perfection nor offering a meaningful valuation discount. The portfolio's weighted current ratio of 2.27 reflects adequate near-term financial stability. Overall, the valuation setup reads as a balance between expected growth and execution risk, with liquidity acting as an important stabilizer if macro conditions become less favorable.

Margins & Cash Generation

The margin profile breaks down as follows: gross margin sits at 50.08%, operating margin at 22.30%, and free cash flow margin at 22.08%. Gross margins are in good shape, suggesting the holdings maintain pricing discipline at the revenue-to-cost interface. Operating margins are solid, reflecting adequate cost control relative to the revenue base. The portfolio's FCF margin is healthy, indicating solid cash conversion after capital expenditure needs. The full margin profile here is impressive — pricing power, operating leverage, and cash conversion are all working in the same direction.

Growth & Forward Outlook

The near-term directional case rests on two inputs: TTM revenue growth of 13.69% pointing to reasonable revenue execution across the underlying holdings. In parallel, analysts project moderate appreciation over the next 12 months based on current consensus targets. The two figures measure different things — one reflects what businesses are actually delivering, the other what the market expects them to deliver. The extent to which these signals converge or diverge will likely be a primary driver of realized returns relative to current expectations. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Conclusion

Strong Buy

Reviewed in aggregate, this is a high-quality profile with few clear structural weaknesses — a combination that historically tends to support above-average long-term outcomes.

These findings are based solely on the metrics presented and do not constitute an investment recommendation. Always perform your own due diligence before committing capital.